Pharmacologia2044-46482044-4656Science International10.3923/pharmacologia.2015.125.130Tephrosia purpurea against Haloperidol Induced Parkinsons Disease Model]]>RajaramCuddapah ReddyKandula Ravindra SekharKothapalli Bonnth Chandra 4201564Background and Objectives: Parkinsons Disease (PD) is a chronic neurodegenerative disorder characterized by the progressive loss of the dopaminergic neurons in the substantia nigra pars compacta which innervates the dorsal striatum. Haloperidol was used to induce Parkinsons disease in experimental rats and the present study investigates the neuroprotective activity of Tephrosia purpurea on haloperidol induced Parkinsons disease model. Methodology: The present study was carried out on Sprague-Dawley rats, where Parkinsons disease was induced by haloperidol. In the current investigation, rats were randomly separated into five groups and then test animals received ethanol extract of Tephrosia purpurea (EET) at dose of 200 and 400 mg kg-1 for 21 days. Catalepsy and muscle rigidity were assessed. In addition, antioxidant levels and histopathological studies were carried out. Results: Ethanol extract of Tephrosia purpurea (EET) showed significant and dose dependent increase in behavioral activity and improved muscular coordination. Significant reduction of lipid peroxidation (LPO), increased antioxidant enzymes like Catalase (CAT) and non-enzymatic activity of reduced glutathione (GSH) in extract treated groups was observed as compared to control group. Conclusion: The EET possesses significant antioxidant activity and renders neuroprotection which was more pronounced at the dose of 400 mg kg-1 against haloperidol induced neurotoxicity.]]>Roger, C.D., I.G. Lawrence, H.M. Margery, I.S. Jacob and S.W. Arthur,1996pp: 30-40pp: 30-40Karch, A.M.,2009pp: 850-874pp: 850-874Dauer, W. and S. Przedborski,200339889909Joy, A.E., M. Shyamjith and K. ShankarBhat,2012Moringaoleifera on haloperidol induced catalepsy in mice models.]]>4543545Nair, V., A. Arjuman, P. Dorababu, H.N. Gopalakrishna, U.C. Rao and L. Mohan,2007126480484Gopalakrishnan, S., E. Vadivel and K. Dhanalakshmi,2010Tephrosia purpurea Linn. aerial and root extracts.]]>311031106Pavana, P., S. Sethupathy and S. Manoharan,2007Tephrosia purpurea seed extract in streptozotocin induced diabetic rats.]]>227783Despande, S.S., G.B. Shah and N.S. Parmar,2003Tephrosia purpurea in rats Inidan.]]>35168172Zazpe, A., I. Artaiz, A. Innerarity, E. del Olmo and E. Castro et al.,2006In vitro and in vivo characterization of F-97013-GD, a partial 5-HT 1A agonist with antipsychotic-and antiparkinsonian-like properties.]]>51129140Abdel-Aal, R.A., A.A.A. Assi and B.B. Kostandy,2011659169176Kraus, R.L., R. Pasieczny, K. Lariosa‐Willingham, M.S. Turner, A. Jiang and J.W. Trauger,200594819827Rambabu, B., S. Kokkula, T. Kiran, D. Rajakumar, T. Ramchander and D. Kemisetti,2012Tephrosiapurpurea (Linn).]]>4275278Kim, M.S., J.I. Lee, W.Y. Lee, S.E. Kim,2004Ginkgo biloba L. extract in a rat model of Parkinson's disease.]]>18663666Shalavadi, M.H., V.M. Chandrashekhar, S.P. Avinash, C. Sowmya and A. Ramkishan,2012Stereospermum suaveolens DC against 6-OHDA induced Parkinson's disease model.]]>44737743Patel, A., A. Patel, A. Patel and N.M. Patel,2010Tephrosia purpurea linn leaves (Leguminosae).]]>2152158Chandra, S., X. Chen, J. Rizo, R. Jahn and T.C. Sudhof,20032781531315318Rogers, D.C., J.O. Peters, J.E. Martin, S. Ball and S.J. Nicholson et al.,20013068992Kabra, M.P., S.S. Bhandari, A. Sharma and R.B. Gupta,20143141144